pracinostat   Click here for help

GtoPdb Ligand ID: 8365

Synonyms: SB 939 | SB-939
Compound class: Synthetic organic
Comment: Pracinostat is an orally available, potent pan-HDAC inhibitor [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 70.39
Molecular weight 358.24
XLogP 3.19
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCc1nc2c(n1CCN(CC)CC)ccc(c2)C=CC(=O)NO
Isomeric SMILES CCCCc1nc2c(n1CCN(CC)CC)ccc(c2)/C=C/C(=O)NO
InChI InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
InChI Key JHDKZFFAIZKUCU-ZRDIBKRKSA-N
No information available.
Summary of Clinical Use Click here for help
In March 2014, the US FDA granted pracinostat orphan designation for the treatment of the rare disease acute myelocytic leukemia (AML). In addition, the drug is currently being tested in Phase 2 trials in combination with azacitidine for the treatment of newly diagnosed AML in elderly patients (NCT01912274) and a further Phase 2 trial is assessing pracinostat + the Janus kinase inhibitor ruxolitinib in patients with myelofibrosis (MF) (see NCT02267278).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
HDAC inhibitors have shown clinical efficacy in AML, myelodysplastic syndrome and myeloproliferative neoplasms [2,4]. The HDAC inhibitor vorinostat was the first compound designed to inhibit HDACs to be approved for clinical use. HDAC inhibition increases acetylation of histone H3 and leads to downstream activation of the PI3K/Akt and MAPK/Ras signaling pathways and ultimately results in cell cycle arrest and apoptosis [1]. Mithraprabhu et al (2010) review the use of HDAC inhibitors in myeloproliferative neoplasms, and discuss the benefits of combination therapies with kinase inhibitors [2].